Level 34, 50 Bridge Street
New South Wales
About Recce Pharma
Recce Ltd is a world-leader in synthetic-polymer antibiotics. The RECCE® antibiotics have been synthesized by an extremely economic method. RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use. Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327.
Founder: Graham JH Melrose
CFO: Peter Williams
41 articles with Recce Pharma
Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives is pleased to announce it has commenced the application process to dual list its stock on the Frankfurt Stock Exhange.
Recce Pharmaceuticals Announces Agreement with Fiona Stanley Hospital for a Phase 1/2 Clinical Trial Evaluating Topical Spray-On Antibiotic RECCE® 327 on Chronic Burn Wounds
Highlights: Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western Australia Study led by world leading burn treatment specialists Study will assess safety and efficacy of RECCE ® 327 against a broad range of infectious disease on chronic burn wounds in up to 30 patients
From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.
Highlights: RECCE ® 327 and RECCE ® 529 demonstrated dose-dependent activity in-vivo against SARS-CoV-2 virus in Syrian golden hamsters, a well-accepted model of infection Intranasal administration of both compounds supports multiple potential modes of administration against SARS-CoV-2 Company committed to its COVID-19 activities as part of its infectious disease portfolio
Recce Pharmaceuticals Ltd ( ASX: RCE ), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on its clinical programs. Topical Phase I/II Human Clinical Trial Submission Topical Phase I/II human clinical study is on track and progressing well. The Company recently announced it has received Human Research Ethics Approval for its Phase I/II human topical clinical trial in infected burn wounds an
Recce Pharmaceuticals Ltd ( ASX: RCE ), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Japan Patent Office (JPO) has granted Patent Family 3 titled “Anti-virus Agent and Method for Treatment of Viral Infection” , furthering marketing and manufacturing monopolies to February 2037. “Recce’s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented
Recce Pharmaceuticals Receives Ethics Approval to Start Phase I/II Study Evaluating Topical Spray-On Synthetic Antibiotic RECCE® 327 on Chronic Burn Wounds
Highlights : Study will assess safety and efficacy of RECCE ® 327 against a broad range of infectious bacteria on chronic burn wounds in up to 30 patients over two week period Study anticipated to be sponsored by South Metropolitan Health Service , Department of Health, Government of Western Australia (WA) Fiona Stanley Hospital ( B urns U nit) in Perth Western Australia identified as study site SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE)
Recce Pharmaceuticals and Murdoch Children’s Research Institute to Evaluate RECCE® 435 Against Helicobacter pylori Stomach Bacteria
Highlights : Murdoch Children’s Research Institute to evaluate the in-vivo antimicrobial activity of RECCE ® 435 oral formulation against Helicobacter pylori (H. pylori) in preclinical studies program Studies led by H. pylori infectious disease expert Professor Philip Sutton Multiple world-first data opportunities over 12 months study program – anticipated human clinical trial beyond SYDNEY, Australia, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Recce Pharma
9/4/2020Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
9/3/2020Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.
Recce Pharmaceuticals Announces Positive Oral Data on New RECCE® 435 Against Helicobacter Pylori in Animal Model
Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, announced positive efficacy activity against Helicobacter pylori bacteria in rats treated with new antibiotic RECCE® 435, including a favorable toxicity profile in a related study.
Recce Pharmaceuticals to Give Opening R&D Address at 2020 Virtual World Antibiotic Resistance Congress
Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Company ), the Company developing New Classes of Synthetic Anti-infectives, today announced that it will be delivering the Opening R&D Address at the World Anti-Microbial Resistance (AMR) Congress from the 8th – 9th October 2020. Due to the global pandemic, the conference will be held entirely virtually. The two-day World AMR Congress is the largest commercially focused conference with AMR at i
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
Recce Pharmaceuticals Enters Agreement with Path BioAnalytics to Test RECCE® Compounds in Expanded SARS-CoV-2 Program
Highlights: International study will be conducted in a laboratory at a leading academic institution in the U.S. to evaluate anti-viral activity of RECCE ® 327 and new antiviral formulation RECCE ® 529 Expanded program utilizing Centers for Disease Control (CDC) SARS-CoV-2 clinical isolate SARS-Related Coronavirus 2, Isolate USA-WA1/2020 Preliminary data anticipated September 2020 SYDNEY, Australia, July 16, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Compa
Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Company ), the Company developing new classes of synthetic anti-infectives, today announced the appointment of Alan W. Dunton, M.D., to its Board of Directors as an independent Non-Executive Director and as a member of the Company’s Audit & Risk and Remuneration & Nomination Committees. “On behalf of all the team at Recce, we welcome Dr. Dunton to our Board of Directors,” stated Dr. John Pre
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of broad-spectrum synthetic antibiotics, today announced the completion of Dr. Graham Melrose’s executive service agreement as Chief Research Officer and his resignation as Executive Director from the Board. Dr. Melrose said: “Recce was formed with a mission to address the global health threat of antibiotic resistance and I feel we have made generationally s
Recce Pharmaceuticals Announces First-Quarter 2020 Financial Results and Provides Operational Highlights
Recce Pharmaceuticals Ltd, the company developing a new class of broad-spectrum synthetic antibiotics, reported its March 2020 quarter results and operational highlights.
Recce Pharmaceuticals Announces More Positive Data on RECCE® 327 Against MRSA Superbug in Burn Wound Animal Model
Highlights: Statistically significant reduction in MRSA superbug bacterial load and higher percentage of wound contraction with RECCE ® 327 as compared to Soframycin in rat model for topical burns Study reinforces the potential of RECCE ® 327 against drug-resistant superbugs
Recce Pharmaceuticals Announces Positive Data on RECCE® 327 Against Influenza A Respiratory Virus Infection in Animal Model
Highlights: Dramatic reduction in viral load in the lungs of mice treated with RECCE ® 327 as compared to the approved antiviral drug treated and vehicle control untreated groups RECCE ® 327’s unique mechanism of action reinforces efficacy against both bacterial cells and enveloped viruses SYDNEY, Australia, April 20, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd ( ASX: RCE ), the company developing a new class of broad-spectrum synthetic antibiotics, today announced posit